|1.||Pérez-Tomás, Ricardo: 9 articles (01/2013 - 02/2003)|
|2.||Soto-Cerrato, Vanessa: 7 articles (01/2013 - 12/2003)|
|3.||Montaner, Beatriz: 6 articles (02/2007 - 02/2003)|
|4.||Pérez-Tomás, R: 5 articles (02/2012 - 10/2000)|
|5.||Chang, Chia-Che: 4 articles (12/2012 - 03/2009)|
|6.||Montaner, B: 4 articles (04/2003 - 10/2000)|
|7.||Kalivoda, Eric J: 3 articles (08/2015 - 03/2010)|
|8.||Shanks, Robert M Q: 3 articles (08/2015 - 03/2010)|
|9.||Stella, Nicholas A: 3 articles (08/2015 - 03/2010)|
|10.||Peng, Yu-Ta: 3 articles (12/2012 - 03/2009)|
10/31/2007 - "Prodigiosin is more potent, with IC50 values lower than 1.5 microM in N-type neuroblastoma cells and around 7 microM in the S-type neuroblastoma cell line. "
10/31/2007 - "In this study we report the effect and mechanisms of action of prodigiosin against different human neuroblastoma cell lines: SH-SY5Y, LAN-1, IMR-32 (N-type) and SK-N-AS (S-type). "
10/31/2007 - "Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines."
10/31/2007 - "This mechanism of action differs from those induced by conventional chemotherapeutic drugs, suggesting a possible role for prodigiosin to enhance the effect of antitumor agents in the treatment of neuroblastoma."
09/01/2015 - "Downregulation of survivin by the anticancer agent prodigiosin can efficiently induce apoptosis in cancer cells. "
06/01/2015 - "Genomic damage induced by prodigiosin was observed in all tumor lines as well as the control line. "
06/01/2015 - "Differential genomic damage in different tumor lines induced by prodigiosin."
01/01/2015 - "Prodigiosin as a secondary metabolite of Serratia marcescens induces apoptosis in various kinds of cancer cells with low toxicity on normal cells. "
09/01/2014 - "Prodigiosin release from an implantable biomedical device: kinetics of localized cancer drug release."
01/01/2013 - "A Serratia marcescens PigP homolog controls prodigiosin biosynthesis, swarming motility and hemolysis and is regulated by cAMP-CRP and HexS."
01/01/2013 - "marcescens conferred pleiotropic phenotypes including the loss of swarming motility, hemolysis, and severely reduced prodigiosin and serratamolide synthesis. "
08/01/2015 - "EepR and the putative sensor kinase EepS were necessary for the biosynthesis of secondary metabolites, including prodigiosin- and serratamolide-dependent phenotypes, swarming motility, and hemolysis. "
07/01/1978 - "A Serratia marcescens biotyping system using eight carbon sources (benzoate, DL-carnitine, m-erythritol, 3-hydroxybenzoate, 4-hydroxybenzoate, lactose, D-quinate, and trigonelline), a tetrathionate reduction test, production of prodigiosin, and horse blood hemolysis was derived from a recent numerical taxonomic study (Grimont et al., J. "
|4.||Colonic Neoplasms (Colon Cancer)
02/15/2014 - "In this study, we report the identification of prodigiosin that can reactivate p53 family-dependent transcriptional activity in p53-deficient human colon cancer cells. "
03/16/2001 - "These results indicate that prodigiosin induces apoptosis in colon cancer cells."
03/16/2001 - "Here we characterize the apoptotic action of prodigiosin in colon cancer cells. "
03/16/2001 - "Prodigiosin-induced apoptosis in human colon cancer cells."
11/26/2005 - "Non-apoptotic concentrations of prodigiosin (H+/Cl- symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells."
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|2.||DNA (Deoxyribonucleic Acid)
|4.||Quinic Acid (Quinate)
|1.||Respiratory Therapy (Therapy, Respiratory)